TG Therapeutics
TGTX
46 hedge funds and large institutions have $33.6M invested in TG Therapeutics in 2013 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 18 increasing their positions, 6 reducing their positions, and 7 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 6
188% more capital invested
Capital invested by funds: $11.7M → $33.6M (+$21.9M)
143% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 7
28% more funds holding
Funds holding: 36 → 46 (+10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BM
Bridger Management
New York
|
+$9.17M |
| 2 |
Jennison Associates
New York
|
+$5.33M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$3.67M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$3.67M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$724K |
| 2 |
Morgan Stanley
New York
|
-$211K |
| 3 |
Jane Street
New York
|
-$155K |
| 4 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$122K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$97.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
JP Morgan Chase
New York
| – | -$73K | -11,491 | Closed |
|
|
SFPIA
52
Stevens First Principles Investment Advisors
Newport Beach,
California
| – | -$6K | -1,000 | Closed |
|
TGTX Hedge Fund Activity: Q3 2013 in Review
46 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q3 2013, worth a combined $33.6M — up 188% from $11.7M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new TGTX positions and 7 closed out — a net gain of 10 holders — while 18 added to existing stakes and 6 trimmed.
The largest buyer was Bridger Management, opening a new position worth an estimated $9.17M. The largest seller was Goldman Sachs, exiting entirely with an estimated $724K sold.
- 46 institutional investors held TG Therapeutics (TGTX) as of Q3 2013, up from 36 in Q2 2013.
- Funds reported $33.6M of TG Therapeutics stock for Q3 2013, up 188% quarter-over-quarter.
- 17 funds opened new TG Therapeutics positions in Q3 2013 and 7 closed out, a net change of +10 holders.
- The largest TG Therapeutics buyer in Q3 2013 was Bridger Management, an estimated $9.17M added.
- The largest TG Therapeutics seller in Q3 2013 was Goldman Sachs, an estimated $724K sold.
Based on aggregated 13F filings for Q3 2013.